ABOUTWe are making the history
of the global pharmaceutical industry.

About

  • OUR MISSION
    Better Life through Better Medicine
    Contributing to improved quality of life and
    public welfare by developing quality medicines

    A company that has achieved numerous
    ‘firsts,’ ‘bests’ and ‘very bests’

    Dedicated to pharmaceuticals since its foundation,
    Chong Kun Dang has overcome many challenges,
    while continuing to grow and contribute to the
    advancement of Korea’s pharmaceutical industry.

    In the days when Korea imported 100% of the raw
    materials required for medicines from abroad,
    we built Korea’s largest plants for chemical
    synthesis and fermentation, making it possible to
    produce pharmaceutical ingredients locally using
    our own technology. From there, we had driven
    Korean Pharmaceutical Industry with this
    breakthrough on the path toward modernization.

    Furthermore, we became the first Korean pharmaceutical company to export products to the US
    market through the obtainment of the U.S. FDA approval.
    Now, on its 75th anniversary, we promise to put all efforts to lead continuous change and innovation,
    positioning Chong Kun Dang as a global pharmaceutical company with a competitive edge in the
    international market.

    CHONG KUN DANG about
    President Young-Joo Kim
    Foundation May 7, 1941 (Spin off on : November 5, 2013)
    Business Line Manufacturing, Sales and Marketing of Medicine
    Paid in Capital 23,5 Bil. (Won)
    Head Office 8, Chungjeong-ro, Seodaemun-gu, Seoul, Korea
    TEL/FAX 82-2-2194-0300 / 82-2-2194-0369
    Homepage www.ckdpharm.com
  • Product Portfolio

    Chong Kun Dang Pharmaceutical Corp. is one of leading Korean pharmaceutical manufacturers and has a great
    strength on domestic sales not only with prescription drugs indicated for anti-hypertension, anti-hyperlipidemia
    and anti-diabetics but also with OTC drugs such as Penzal, Prefemine, Modcol and consumer health such as
    insecticides, hairdye, etc.

    Prescription
    Chong Kun Dang has a complete portfolio of prescription
    pharmaceutical products for the entire segment and therapeutic
    classes, supported not only by own-developed NCE drugs
    Camptobell as a anticancer and anti-diabetic, Duvie, but also
    anti-hypertension Dilatrend, Telminuvo, anti-hyperlipidemia Lipilou,
    and immunosuppressant Tacrbell.
    Over-the-counter (OTC)
    Chong Kun Dang’s OTC drugs consist of products known for their
    therapeutic benefits, as well as supplements and other preventive
    products. Penzal which is best-seller for headache in Korea,
    Zelcom as No.1 antithelmintic, and fast-effective digestive Sok-
    chung drink carry strong brand names that have dominated the
    market over the past few decades. In recent days, some of Chong
    Kun Dang’s preventive OTCs are positioning to advance women’s
    health such as Prefemine for premenstrual syndrome and
    Simidona for menopause symptom, Bolgre for iron supplements.
    Health Supplements
    Chong Kun Dang provides high-quality healthcare supplements
    with preventive benefits including prebiotics complex Prelacto and
    Premium Omega-3+vitamin series caring for modern people in their
    busy life.
    Consumer Health
    Chong Kun Dang’s selection of healthy beverage products range
    from Sok-chung cool, and Ja-Whang, San-e-nun-Sam with
    red-ginseng based healthy drink to insecticides Jjong aerosol.

    Global business presence

    Chong Kun Dang is expanding the market in worldwide with strategic products in immunosuppressants,
    anti-cancers and antibiotics. In order to grow strength in Glocalization (Globalization + Localization),
    Chong Kun Dang opened representative office in Vietnam since 2012 and established Joint Venture company
    in Indonesia in 2015.

    수출 이미지

    Growth Drivers

    Chong Kun Dang’s manufacturing site in CheonAn city supply quality
    prescribed products meeting with global standard into worldwide as Japan,
    China, South-east Asian, MENA and African countries.
    In recent, it is being strengthen to dominant market share in ASEAN region
    through Indonesian JV company, VN rep. office and further footholds.

    인도네시아JV 이미지

    Indonesia JV

    In September 2015, Chong Kun Dang has established the joint venture
    company PT CKD OTTO Pharmaceuticals with PT OTTO Pharmaceutical Ltd.
    which is one of leading local pharmaceutical companies in Indonesia. In the
    future, PT CKD OTTO as a production base not only for domestic market, but
    only for near Asian, MENA and EU countries, will manufacture and distribute
    anti-cancer drugs such as Belloxa, Gemtan, etc. through which Chong Kun
    Dang has global competitiveness.

    베트남 대표사무소 이미지

    Vietnam Rep. Office

    Since Chong Kun Dang’s Vietnam representative office has been established
    in 2012, it has been raised company awareness in domestic by expanding
    the pipeline of prescription drugs as well as health care products.
    Through various promotion activity, oncology products (Belloxa, Gemtan),
    anti-hypertensives (Candemore plus), antibiotics (Kmoxilin) and various
    health care products including red-ginseng liquid, collagen capsule,
    probiotics, etc are being distributed in nationwide.

    Licensing and Tech Transfer

    Chong Kun Dang is focused on in-licensing novel drugs which offers better solution for chronic disorders such as
    diabetes and cardiovascular diseases, as well as for anti-cancer therapies and neurological diseases with high
    medical unmet needs. Having developed Duvie®, the new drug for type II diabetes, Chong Kun Dang is actively
    expanding its global presence with the best-in-class anti-cancer pipelines (CKD-516 and CKD-581) and dyslipidemia
    therapy (CKD-519), starting from the neighboring Asian markets. Further, Chong Kun Dang has an in-house
    technology platform for HDAC6-selective inhibitors which provides the novel mechanism of action.
    We are enthusiastically preparing for the global market entry via strategic business diversification, specifically
    targeting auto-immune diseases, neurological disorders, and cancer.

    Business Alliance

    Supported by its long presence in Korean pharmaceutical industry and strong sales and marketing capacity,
    Chong Kun Dang is involved in numerous business alliance relationships with the most prestigious multinational
    companies in various fields.
    Over the last decade, Chong Kun Dang has formed the partnership with MNCs such as Bayer, Roche, Allergan, Pfizer,
    and MSD and, as a result, Chong Kun Dang has an unrivaled leadership in the local market enhanced by its robust
    product portfolio which now covers a broad range of therapeutic classes with innovative, outstanding drugs.
    Chong Kun Dang will continue to work towards mutual development through global business partnering.

    독일
    GERMANY
    스위스
    SWITZERLAND
    미국
    USA
    일본
    JAPAN
    프랑스
    FRANCE
    이탈리아
    ITALY
    코스타리카
    COSTA RICA
    캐나다
    CANADA
    사업제휴 국가
    Country Affiliated Companies Product Names
    GERMANY Bayer
    B.Braun
    Riemser
    Engelhard
    Merz
    Avelox®, Ciprobay®, Ciprouro®
    Hospital Solns, Nutriflex®, Lipidem®
    Ismo®
    Tyrosur®
    Mederma®
    SWITZERLAND Roche
    Zeller
    Dilatrend®, Tamiflu®, Kytril®, etc
    Prefemin®, Cimidona®
    USA Zafgen
    Cara
    S1 Biopharma
    Allergan
    MSD
    Pfizer
    CKD-732M
    CKD-943(CR-845)
    Lorexys
    Restasis®, Relestat®
    Januvia® Family, Vytorin®, Atozet®
    Xalatan®, Xalacom®
    JAPAN Mitsubishi Tanabe
    Ayumi
    Asahi Kasei
    Kyorin
    ReqMed
    Depas®
    Rimatil®
    Bredinin®, Elcitonin®
    Baccidal®
    Penpol®
    FRANCE Expanscience
    Vivacy
    Neovacs
    Imotun®
    Stylage®
    IFN-alpha kinoid
    ITALY Menarini
    Italfarmaco
    Neuropacid®
    Gliatilin®
    COSTA RICA Newport PrinosineⓇ
    CANADA Valeant
    Cardiome
    Colazal®
    Brinavess®
  • Cheon-An plant located in Cheon-An City, ChungCheongNam Do with area of
    13,700㎡ and gross floor area of 5,000㎡ is a high-tech manufacturing site
    where the process of dispensing raw materials, production, packaging and
    release of finished products is controlled by automated warehousing
    system.

    Cheon-An plant established aspects of global pharmaceutical production facility through completion
    of separated cephalosporin and penicillin plants with level of cGMP in 2013, and certified the GMP
    (Good manufacturing practice) compliance through inspections of several domestic and foreign
    regulatory authorities. Also, the plant has maximized the operating efficiency successively starting
    with establishment of SAP ERP (Enterprise Resource Planning) in 2010, QMS (Quality Management
    System) and LIMS (Laboratory Information System) for efficient substantial manufacturing control
    and quality assurance.
    Cheon-An plant with high-tech production facility, excellent manufacturing and testing equipment and
    optimized manufacturing environment is steadily evolving today through continued securing of human
    resources and facility investment, and plays a pivotal role as a production base to realize value and
    vision of global Chong Kun Dang Pharmaceutical Corp.

    Feature

    자동화 창고 이미지

    Automatic warehouse

    The warehouse establishes unmanned transport system for entire
    logistical flows such as material dispensing, manufacturing, packaging
    and warehousing of finished products by using LGV and RGV,
    and supplies the medicinal product to hospitals, pharmacies, general
    practitioners and so on through digital picking system.

    QC 실험실 이미지

    QC Laboratory

    Quality control team determines conformity of raw materials,
    packaging materials and finished products to established
    specifications after testing, and controls the quality so that customer
    take safe medicinal products.
    The laboratory conducts accurate test and contributes to GMP
    compliance and development based on quality talent and advanced
    analysis equipment.

    약품 생산 이미지

    Manufacture of over the counter and prescription drug

    The process from materials to manufacture finished product is
    controlled in compliance with GMP through advanced automation
    equipment and verified process control.

    Manufacturing Process

  • Hyo-Jong Research Institute

    Hyo : 曉 (Dawn), Jong : 鐘 (Bell)
    Opening a new era by ringing the bell

    Since the foundation, Chong Kun Dang has been
    pursuing a disease-free society by developing
    excellent medicines.
    Cognizant of the importance of drug discovery,
    Chong Kun Dang was the first in Korea to run its
    own research institute; it also invested a huge
    portion of its resources in nurturing and training
    research manpower.

    Chong Kun Dang Research Institute is
    characterized by three independent laboratories:
    The New Drug Discovery Labs, for identifying
    innovative drug candidates,
    The Technology Development Labs, dedicated to
    generic drugs, APIs, and botanical drugs,
    and the Bio Research Labs for developing
    antibodies, vaccines, and recombinant proteins. 

    Chong Kun Dang was able to stand as one of the top local pharmaceutical companies with
    distinguished achievements in drug development including the following :

    ·
    Two new drugs, Duvie (type II diabetes) and Camtobell (cancer), were developed successfully.
    ·
    CKD-732 (Beloranib), which was developed by Chong Kun Dang and licensed out to an US-based
    specialty pharma Zafgen, is now in development for Prader-Willi syndrome (P III) and severe obesity
    (P II) in the US and EU.
    ·
    CKD-11101, a biosimilar product to treat anemia is successfully in phase III clinical trial.

    R&D Investment
    Chong Kun Dang strives to develop innovative new drugs by investing a significant amount of R&D
    expenditure, spending 13.3% of net sales in 2014.
    In order to accomplish our vision, Chong Kun Dang continuously increases R&D investment with 21%
    of annual growth of since 2009.

    R&D Vision & Strategy

    R&D Expenditure